sar444881
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 15, 2025 (NCT06651593)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- LILRB1INHIBITOR
LILRB1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06651593 | Phase 2 | Apr 15, 2025 | Regeneron, Sanofi, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 1 | 0 | 1 | 2025 |
| Sanofi | For profit | 1 | 0 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1